Commentary|Videos|November 11, 2024
The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
Author(s)Haley M. Hill, PA-C
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss HER2-mutant NSCLC testing, treatment selection, and sequencing strategies.
OS in the LIVERATION trial of namodenoson in advanced HCC appeared longer than anticipated, prompting consideration of an earlier interim analysis.
The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.
Durvalumab plus tarlatamab significantly improved OS and PFS vs durvalumab alone as maintenance in extensive-stage SCLC, per topline phase 3 data.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera
5